Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani, Kamal (Leukemia Service)
Gomez-Arteaga, Alexandra (Memorial Sloan Kettering Cancer Center)
Madero-Marroquin, Rafael (Icahn School of Medicine. Mount Sinai St Luke's and Mount Sinai West)
Zhang, Mei-Jie (Medical College of Wisconsin)
Bo-Subait, Khalid (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Sanchez, Jonathan (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Wang, Hai-Lin (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)
Aljurf, Mahmoud (King Faisal Specialist Hospital Center and Research)
Assal, Amer (Columbia University Irving Medical Center)
Bacher, Vera Ulrike (Bern University Hospital)
Badawy, Sherif M. (Northwestern University Feinberg School of Medicine)
Bejanyan, Nelli (Department of Blood and Marrow Transplant and Cellular Immunotherapy. Moffitt Cancer Center)
Bhatt, Vijaya Raj (University of Nebraska Medical Center)
Bredeson, Christopher (Ottawa Hospital Research Institute)
Byrne, Michael (Vanderbilt University Medical Center)
Castillo, Paul (UF Health Shands Children's Hospital)
Cerny, Jan (University of Massachusetts Medical Center)
Chhabra, Saurabh (Medical College of Wisconsin)
Ciurea, Stefan Octavian (The University of Texas MD Anderson Cancer Center)
DeFilipp, Zachariah (Massachusetts General Hospital (Boston))
Farhadfar, Nosha (Division of Hematology/Oncology. University of Florida College of Medicine)
Gadalla, Shahinaz (Division of Cancer Epidemiology and Genetics. National Cancer Institute (NCI) Clinical Genetics Branch. National Institutes of Health (NIH))
Gale, Robert Peter (Imperial College London)
Ganguly, Siddhartha (Division of Hematological Malignancy and Cellular Therapeutics. University of Kansas Health System)
Gowda, Lohith (Section of Hematology. Department of Medicine. Yale University School of Medicine. Yale Comprehensive Cancer Center. Yale New Haven Hospital)
Grunwald, Michael R. (Department of Hematologic Oncology and Blood Disorders. Levine Cancer Institute. Atrium Health)
Hashmi, Shahrukh (Oncology Center. King Faisal Specialist Hospital and Research Center)
Hildebrandt, Gerhard (Markey Cancer Center. University of Kentucky)
Kanakry, Christopher G. (Experimental Transplantation and Immunology Branch. Center for Cancer Research. NCI. NIH)
Kansagra, Ankit (UT Southwestern Medical Center. Blood and Marrow Transplant Program)
Khimani, Farhad (H Lee Moffitt Cancer Center and Research Institute)
Krem, Maxwell (Markey Cancer Center. University of Kentucky College of Medicine)
Lazarus, Hillard (Department of Medicine. University Hospitals Case Medical Center. Seidman Cancer Center. Case Comprehensive Cancer Center. Case Western Reserve University)
Liu, Hongtao (Section of Hematology/Oncology. University of Chicago Medicine)
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau)
Michelis, Fotios V. (Allogeneic Blood and Marrow Transplant Program. Princess Margaret Cancer Centre)
Nathan, Sunita (Section of Bone Marrow Transplant and Cell Therapy. Rush University Medical Center)
Nishihori, Taiga (The Fred and Pamela Buffett Cancer Center. University of Nebraska Medical Center)
Olsson, Richard (Uppsala University)
Reshef, Ran (Columbia Center for Translational Immunology. Columbia University Medical Center)
Rizzieri, David (Division of Hematologic Malignancies and Cellular Therapy. Duke University)
Rowe, Jacob M. (Department of Hematology. Shaare Zedek Medical Center)
Savani, Bipin N. (Division of Hematology/Oncology. Department of Medicine. Vanderbilt University Medical Center)
Seo, Sachiko (Dokkyo Medical University)
Sharma, Akshay (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica))
Solh, Melhem (The Blood and Marrow Transplant Group of Georgia. Northside Hospital)
Ustun, Celalettin (Hematology. Oncology. and Cell Therapy. Rush University Medical Center)
Verdonck, Leo F. (Department of Hematology and Oncology. Isala Clinic)
Hourigan, Christopher (National Heart Lung. and Blood Institute. NIH)
Sandmaier, Brenda (Clinical Research Division. Fred Hutchinson Cancer Research Center)
Litzow, Mark (Division of Hematology and Transplant Center. Mayo Clinic Rochester)
Kebriaei, Partow (The University of Texas MD Anderson Cancer Center)
Weisdorf, Daniel (Division of Hematology. Oncology and Transplantation. Department of Medicine. University of Minnesota)
Zhang, Yanming (Department of Pathology. Memorial Sloan Kettering Cancer Center)
Tallman, Martin S. (Department of Pathology. Memorial Sloan Kettering Cancer Center)
Saber, Wael (Center for International Blood and Marrow Transplant Research (CIBMTR). Department of Medicine)

Fecha:	2022
Resumen:	Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1. 27; P 5. 01; HR, 1. 71; P,. 001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1. 26; P 5. 002, and HR, 1. 47; P,. 001), as was overall survival (HR, 1. 32; P,. 001, and HR, 1. 45; P,. 001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Publicado en:	Blood advances, Vol. 6 Núm. 3 (august 2022) , p. 828-847, ISSN 2473-9537

DOI: 10.1182/bloodadvances.2021004881
PMID: 34551064

20 p, 1.9 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados